Like Dr. House in the series of the same name, doctors sometimes come up against enigmas when faced with certain pathologies. The aim of the OrphaMine platform developed as part of the ANR Hybride project is to increase specialists’ understanding of rare diseases. The platform has been tested in-house and will soon be offered to a broader panel made up of doctors, researchers and representatives of the pharmaceutical industry.
